Skip to content

SION SION Business Segments — Fees paid to licensors

Similar metrics at other companies

Travere Therapeutics, Inc. logo
TVTXReportable Segment — Royalty expense
$24.82M+99.7%
Amgen logo
AMGNReportable Segment — Royalty Expense
$564M+28.2%
Lexicon Pharmaceuticals logo
LXRXReportable Segment — Royalties and other revenue
$12K
Acadia Pharmaceuticals logo
ACADReportable Segment Aggregation Before Other Operating — Royalty Expense
$13.13M+17.4%
Adeia logo
ADEAIntellectual Property Licensing — Segment Reporting Other Item Amount
$5.3M+18.9%
PVH logo
PVHLicensing Segment — Segment Reporting, Other Segment Item, Amount
$14.2M-6.0%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.86B
Enterprise value$1.8B

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept sionna:FeesPaidToLicensors.

The official record: SION’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's business segments — fees paid to licensors.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's business segments — fees paid to licensors?
SION (SION) reported business segments — fees paid to licensors of $5.75K in Q4 2025.
How has SION's business segments — fees paid to licensors changed year-over-year?
SION's business segments — fees paid to licensors decreased by 99.6% year-over-year, from $1.38M to $5.75K.
What does business segments — fees paid to licensors mean?
Tracks the cash payments made to third-party licensors for the rights to use intellectual property, patents, or proprietary technology within a business segment. These fees are critical for companies relying on in-licensed assets to drive their research and development programs. Monitoring these payments helps investors understand the long-term cost structure and royalty obligations associated with the segment's technology portfolio.